Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Capital Expenditures (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Capital Expenditures for 6 consecutive years, with -$45000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures fell 101.35% to -$45000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $7000.0, a 99.82% decrease, with the full-year FY2025 number at $7000.0, down 99.82% from a year prior.
  • Capital Expenditures was -$45000.0 for Q4 2025 at TScan Therapeutics, up from -$2.8 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $7.4 million in Q3 2021 to a low of -$2.8 million in Q3 2025.
  • A 5-year average of $868150.0 and a median of $560500.0 in 2022 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: soared 2837.5% in 2024, then tumbled 153.82% in 2025.
  • TScan Therapeutics' Capital Expenditures stood at $2.2 million in 2021, then tumbled by 105.79% to -$128000.0 in 2022, then skyrocketed by 2289.84% to $2.8 million in 2023, then rose by 19.34% to $3.3 million in 2024, then tumbled by 101.35% to -$45000.0 in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Capital Expenditures are -$45000.0 (Q4 2025), -$2.8 million (Q3 2025), and $2.5 million (Q2 2025).